Literature DB >> 8591695

Racial, ethnic and gender differences in response to medicines.

H W Matthews1.   

Abstract

In recent years, researchers have found significant differences among racial, ethnic and gender groups in the ways they respond to and metabolize drugs, and experience side effects. Most studies have focused on cardiovascular, psychotropic and central nervous system drugs. Alcohol, antihistamines and analgesics are other agents with varying effects among different racial, ethnic and gender groups. The Food and Drug Administration (FDA) noted last year that Asian-Americans show increased sensitivity to beta blockers. It also observed that African-Americans are less responsive to ACE inhibitors. Gender differences in drug therapy seem to basically evolve around psychotropic drugs. Environmental, cultural and genetic factors are involved in determining response to medicines in different racial, ethnic and gender groups. Continued research in this area will undoubtedly reveal significant information regarding racial, ethnic and gender differences in response to drugs. These developments will impact on how clinical trials are conducted and challenge conventional thoughts regarding restricted formularies.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8591695     DOI: 10.1515/dmdi.1995.12.2.77

Source DB:  PubMed          Journal:  Drug Metabol Drug Interact        ISSN: 0792-5077


  9 in total

Review 1.  Recommendations of the clinical trials consensus panel. National Medical Association.

Authors: 
Journal:  J Natl Med Assoc       Date:  2000-10       Impact factor: 1.798

Review 2.  Evidence based medicine and justice: a framework for looking at the impact of EBM upon vulnerable or disadvantaged groups.

Authors:  W A Rogers
Journal:  J Med Ethics       Date:  2004-04       Impact factor: 2.903

3.  What of Asian, African, and South American patients?

Authors:  Suranjith L Seneviratne; Padmalal Gurugama; Devaka J Fernando
Journal:  BMJ       Date:  2007-01-06

4.  An open-label extension study evaluating the safety and efficacy of romiplostim for up to 3.5 years in thrombocytopenic Japanese patients with immune thrombocytopenic purpura (ITP).

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Koji Iwato; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Satoshi Hashino; Haruhiko Ninomiya; Shinichiro Mori; Yuji Yonemura; Kensuke Usuki; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2012-04-25       Impact factor: 2.490

5.  Representation of South Asian people in randomised clinical trials: analysis of trials' data.

Authors:  Su Mason; Mahvash Hussain-Gambles; Brenda Leese; Karl Atkin; Julia Brown
Journal:  BMJ       Date:  2003-06-07

6.  Romiplostim for the treatment of chronic immune thrombocytopenia in adult Japanese patients: a double-blind, randomized Phase III clinical trial.

Authors:  Yukari Shirasugi; Kiyoshi Ando; Koji Miyazaki; Yoshiaki Tomiyama; Shinichiro Okamoto; Mineo Kurokawa; Keita Kirito; Yuji Yonemura; Shinichiro Mori; Kensuke Usuki; Koji Iwato; Satoshi Hashino; Helen Wei; Richard Lizambri
Journal:  Int J Hematol       Date:  2011-06-25       Impact factor: 2.490

Review 7.  A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics?

Authors:  Lorena Baietto; Silvia Corcione; Giovanni Pacini; Giovanni Di Perri; Antonio D'Avolio; Francesco Giuseppe De Rosa
Journal:  Curr Drug Metab       Date:  2014       Impact factor: 3.731

8.  Improving diversity in study participation: Patient perspectives on barriers, racial differences and the role of communities.

Authors:  Lisa Shea; Jacqueline Pesa; Gabrielle Geonnotti; Valerie Powell; Caryl Kahn; Wesley Peters
Journal:  Health Expect       Date:  2022-06-28       Impact factor: 3.318

9.  Intravenous anidulafungin followed optionally by oral voriconazole for the treatment of candidemia in Asian patients: results from an open-label Phase III trial.

Authors:  Piroon Mootsikapun; Po-Ren Hsueh; Deepak Talwar; Vilma M Co; Viraj Rajadhyaksha; Moh-Lim Ong
Journal:  BMC Infect Dis       Date:  2013-05-15       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.